Business
Launch of New Health dedicated GLP/peptides brand
MedPal AI plc has launched New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market, supported by a £1.3 million national consumer marketing campaign. This strategic move aims to capture growth in the GLP-1 category, anticipating a potential UK approval of an oral GLP-1 medication in summer 2026, which could significantly broaden the addressable market. The UK prescription weight-loss medication market is projected to grow at a compound annual growth rate of approximately 25% from 2026 to 2033, reaching an estimated £1.85 billion by 2033. New Health will operate separately from the MedPal Clinic app to offer a distinct consumer proposition while leveraging MedPal AI's regulated healthcare infrastructure. Disclaimer*
About this update from Medpal Ai Plc
[{"type":"text","content":"\n\n20 May 2026\nMedPal AI plc\n(\"MedPal AI\" or the \"Company\")\nLaunch of New Health on new.co.uk as dedicated GLP-1 and peptides brand\nNew Health to operate as a specialist consumer brand within MedPal AI, positioned for GLP-1 growth and the expected UK oral GLP-1 step-change\n \nMedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy platform, is pleased to announce the launch of New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market opportunity, supported by a £1.3 million national consumer marketing campaign. The launch is being positioned in the context of rapid growth in the GLP-1 category and ahead of the Board's anticipated UK approval of Novo Nordisk's once-daily weight-management pill in summer 2026.\nNew Health will sit separately from the broader MedPal Clinic app and MedPal consumer platform. It has been created to give the Company a sharper consumer brand, acquisition funnel and patient journey for the highly competitive GLP-1 category, while continuing to use MedPal AI's regulated healthcare infrastructure comprising: AI-assisted intake, clinician-led assessment, prescribing where clinically appropriate, automated pharmacy dispensing and ongoing monitoring.\n\nHighlights\n· New Health launched as a specialist sub-brand of MedPal AI focused initially on GLP-1 weight management and, over time, the broader peptides opportunity.\n· The sub-brand will operate separately from the MedPal Clinic app to allow a dedicated consumer proposition in a competitive, brand-led market, while remaining fully connected to MedPal AI's clinical, pharmacy and technology infrastructure.\n· £1.3 million has been committed to a national consumer marketing programme, with performance-led digital activity expected to be a principal component.\n· Marketing campaign is designed to drive traffic to websites new.co.uk and new.uk, to increase initiations of qualified consultations and to grow the New Health recurring patient base.\n· Market context supported by published research indicating significant UK and global GLP-1 growth, including forecast UK prescription weight-loss medication market growth at ...